Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Pharmacokinetic properties, in vitro metabolism and plasma protein binding of govaniadine an alkaloid isolated from Corydalis govaniana Wall

Texto completo
Autor(es):
Marques, Lucas M. M. ; Callejon, Daniel R. ; Pinto, Larissa G. ; de Campos, Michel L. ; de Oliveira, Anderson R. M. ; Vessecchi, Ricardo ; Adhikari, Achyut ; Shrestha, Ram L. S. ; Peccinini, Rosangela G. ; Lopes, Norberto P.
Número total de Autores: 10
Tipo de documento: Artigo Científico
Fonte: Journal of Pharmaceutical and Biomedical Analysis; v. 131, p. 464-472, NOV 30 2016.
Citações Web of Science: 4
Resumo

Govaniadine (GOV) is an alkaloid isolated from Corydalis govaniana Wall. It has been reported to show a different number of biological activities including anti-urease, leishmanicidal and antinociceptive. The present study aims to characterize the GOV in vitro metabolism after incubation with rat and human liver microsomes (RLM and HLM, respectively) and to evaluate its pharmacokinetic properties. The identification of GOV metabolites was conducted by different mass analyzers: a micrOTOF II-ESI-ToF Bruker Daltonics (R) and an amaZon-SLion trap (IT) Bruker Daltonics (R). For the pharmacokinetic study of GOV in rats after intravenous administration, a LC-MS/MS method was developed and applied to. The analyses were performed using an Acquity UPLC (R) coupled to an AcquityTQD detector equipped with an ESI interface. The liver microsomal incubation resulted in new O-demethylated, di-hydroxylated and mono-hydroxylated compounds. Regarding the method validation, the calibration curve was linear over the concentration range of 2.5-3150.0 ng mL(-1), with a lower limit of quantitation (LLOQ) of 2.5 ng mL(-1). This method was successfully applied to a pharmacokinetic study. The profile was best fitted to a two-compartment model, the first phase with a high distribution rate constant (alpha) 0.139 +/- 0.086 min(-1), reflected by the short distribution half-life (t1/2 alpha) 9.2 +/- 8.9 min and the later one, with an elimination half-life (t1/2 beta) 55.1 +/- 37.9 min. The main plasma protein binding was 96.1%. This is a first report in this field and it will be useful for further development of govaniadine as a drug candidate. (C) 2016 Elsevier B.V. All rights reserved. (AU)

Processo FAPESP: 13/17658-9 - Desenvolvimento e validação de métodos cromatográficos e eletroforéticos para posterior aplicação em estudos de biotransformação e metabolismo in vitro - fase 2
Beneficiário:Anderson Rodrigo Moraes de Oliveira
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 13/16496-5 - Avaliação do metabolismo in vitro, in vivo e do perfil farmacocinético do alcalóide govaniadina
Beneficiário:Lucas Maciel Mauriz Marques
Linha de fomento: Bolsas no Brasil - Doutorado
Processo FAPESP: 14/13192-8 - Avaliação da farmacocinética do benznidazol administrado na forma de comprimidos de liberação prolongada e comprimidos pediátricos em coelhos albinos
Beneficiário:Rosangela Gonçalves Peccinini
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 14/23604-1 - Química computacional: uma ferramenta para estudos envolvendo espectrometria de massas, reatividade e mecanismos de reação/fragmentação de compostos orgânicos
Beneficiário:Ricardo Vessecchi Lourenço
Linha de fomento: Auxílio à Pesquisa - Regular